4.7 Article

Preparation and biological evaluation of copper-64-labeled Tyr3 -: Octreotate using a cross-bridged macrocyclic chelator

Journal

CLINICAL CANCER RESEARCH
Volume 10, Issue 24, Pages 8674-8682

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-04-1084

Keywords

-

Categories

Funding

  1. NCI NIH HHS [R24 CA86307, R01 CA93375, R01 CA093375, R01 CA64475, R21 CA100972, 5 R24 CA83060] Funding Source: Medline
  2. NIGMS NIH HHS [T32 GM07200-2] Funding Source: Medline

Ask authors/readers for more resources

Purpose: Somatostatin receptors (SSTr) are expressed on many neuroendocrine tumors, and several radiotracers have been developed for imaging these types of tumors. For this reason, peptide analogues of somatostatin have been well characterized. Copper-64 (t(1/2) = 12.7 hours), a positron emitter suitable for positron emission tomography (PET) imaging, was shown recently to have improved in vivo clearance properties when chelated by the cross-bridged tetraazamacrocycle 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane (CB-TE2A) compared with 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA). Experimental Design: CB-TE2A and TETA were conjugated to the somatostatin analogue tyrosine-3-octreotate (Y3-TATE) for evaluation of CB-TE2A as a bifunctional chelator of Cu-64. The in vitro affinity of each compound for SSTr was determined using a homologous competitive binding assay. In vivo characteristics of both radiolabeled compounds were examined in biodistribution and microPET studies of AR42J tumor-bearing rats. Results: Cu-CB-TE2A-Y3-TATE (K-d = 1.7 nmol/L) and Cu-TETA-Y3-TATE (K-d = 0.7 nmol/L) showed similar affinities for AR42J derived SSTr. In biodistribution studies, nonspecific uptake in blood and liver was lower for Cu-64-CB-TE2A-Y3-TATE. Differences increased with time such that, at 4 hours, blood uptake was 4.3-fold higher and liver uptake was 2.4-fold higher for Cu-64-TETA-Y3-TATE than for Cu-64-CB-TE2A-Y3-TATE. In addition, 4.4-times greater tumor uptake was detected with Cu-64-CB-TE2A-Y3-TATE than with Cu-64-TETA-Y3-TATE at 4 hours postinjection. MicroPET imaging yielded similar results. Conclusions: CB-TE2A appears to be a superior in vivo bifunctional chelator Of (CU)-C-64 for use in molecular imaging by PET or targeted radiotherapy due to both improved nontarget organ clearance and higher target organ uptake of Cu-64-CB-TE2A-Y3-TATE compared with Cu-64-TETA-Y3-TATE.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available